Sagimet Biosciences (SGMT) Total Current Liabilities (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Total Current Liabilities of $5.3 million for Q1 2026, up 3.84% quarter-over-quarter from $5.1 million in Q4 2025.
Sagimet Biosciences (SGMT) Total Current Liabilities (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Total Current Liabilities history runs 5 years deep, the most recent figure standing at $5.3 million for Q1 2026.
- In Q1 2026, Total Current Liabilities changed N/A year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $5.3 million (changed N/A YoY), while the FY2025 annual figure was $5.1 million, up 14.53% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $5.3 million, up from $5.1 million in the prior quarter.
- The five-year high for Total Current Liabilities was $9.1 million in Q3 2025, with the low at $4.5 million in Q4 2024.
- The 5-year median for Total Current Liabilities is $5.3 million (2023), against an average of $5.8 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities declined 21.22% in 2024, then increased 14.53% in 2025.
- Sagimet Biosciences' Total Current Liabilities stood at $5.3 million in 2022, then climbed by 7.1% to $5.7 million in 2023, then slipped by 21.22% to $4.5 million in 2024, then gained by 14.53% to $5.1 million in 2025, then rose by 3.84% to $5.3 million in 2026.
- Business Quant data shows SGMT's Total Current Liabilities at $5.3 million in Q1 2026, $5.1 million in Q4 2025, and $9.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 5.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.42 Mn |
| Mar 31, 2026 | 5.30 Mn |
| Dec 31, 2025 | 5.10 Mn |
| Sep 30, 2025 | 9.15 Mn |
| Jun 30, 2025 | 7.25 Mn |
| Dec 31, 2024 | 4.45 Mn |
| Dec 31, 2023 | 5.65 Mn |
| Sep 30, 2023 | 5.05 Mn |
| Jun 30, 2023 | 5.29 Mn |
| Dec 31, 2022 | 5.28 Mn |